A Comparison of the Cost of Treatment with Atosiban or beta-Sympatomimetic Drugs in Premature Delivery from the Perspective of Health Care Payer - A Pharmaco-Economic Model;Srovnání Nákladů na Léčbu Předčasného Porodu Atosibanem Nebo Beta-sympatomimetiky z Perspektivy Plátce Zdravotní Péče - Farmakoekonomický Model

Ceska Gynekologie

Volumn 69, Issue 2, 2004, Pages 96-105

  Hruby K ^a  

^a Vitkovice vyzkum a vyvoj technicke aplikace as   (Czech Republic)

Author keywords

Atosiban; Pharmaco economy; Premature delivery; Toxolytic drugs

Indexed keywords

ANTIEMETIC AGENT; ATOSIBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARDIOTONIC AGENT; DIURETIC AGENT; DOPAMINE; FENOTEROL; HEPARIN; HEXOPRENALINE; INSULIN; UTERUS SPASMOLYTIC AGENT;

ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DYSPNEA; FEMALE; HEALTH INSURANCE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HOSPITAL; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; LUNG EDEMA; MEDICAL CARE; NAUSEA; PHARMACY; PREMATURE LABOR; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TREMOR; VOMITING;

CZECH REPUBLIC; DRUG COSTS; FEMALE; FENOTEROL; HEALTH CARE COSTS; HEXOPRENALINE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; OBSTETRIC LABOR, PREMATURE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 1942443831     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Souhrn údajů o přípravku Partusisten. Databáze AISLP-ČR, verze 2003.2.
2. Souhrn údajů o přípravku Gynipral. Databáze AISLP-ČR, verze 2003.2.
3. Besinger, R. E., Iannucci, T. A.: Tocolytic therapy. In: Elder, M. G., Lamont, R. F., Romeo, R. (eds.): Preterm Labor, New York, Churchill Livingstone, 1997, s. 243-297.
4. Cole, R. M., Lamont, R. F.: Current perspectives on drug treatment for preterm labour. J. Obstet. Gynaecol., 18, 1998, s. 309-314.
5. Crowley, P., Chalmers, I., Keirse, M. J. N. C.: The effects of corticosteroid administration prior to preterm delivery: an overview from the evidence from controlled trials. Br. J. Obstet. Gynaecol., 97, 1990, s. 11-25.
6. Goodwin, T. M., Paul, R., Silver, H. et al.: The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am. J. Obstet. Gynecol., 150, 1994, s. 734-741.
7. Hall, M. H., Danielian, P., Lamont, R. F.: The importance of preterm birth. In: Elder, M. G., Lamont, R. F., Romeo, R. (eds.): Preterm Labor, New York, Churchill Livingstone, 1997, s. 1-28.
8. Moutquin, J. M., Cabrol, D., Fisk, N. M. et al.: Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br. J. Obstet. Gynaecol., 108, 2001, s. 133-142.
9. Sanchez, L. A.: Pharmacoeconomics: principles. In: DiPiro, J. T., Albert, R. L., Lee, G. C., Matzke, G. R., Wells, B. G., Posey, L. M. (eds.): Pharmacotherapy: A Pathophysiologic Approach, New York, McGraw-Hill, 2002, s. 1-10.
10. Sanchez, L. A., Lee, J. T.: Applied pharmacoeconomics: Modeling data from internal and external sources. Am. J. Health-Syst. Pharm., 57, 2000, s. 146-155.